Pavel Klein, MD, Mid-Atlantic Epilepsy and Sleep Center, Bethesda, MD, describes subgroup analyses evaluating the efficacy and safety of cenobamate in different epilepsy populations and with different concomitant medications. A large pivotal study of cenobamate showed that the drug was well-tolerated, and a subanalysis showed very similar efficacy results to the C017 study (NCT01866111). Another subanalysis was performed looking at whether responses improved if cenobamate was combined with other medications. Results did not show a pattern of better or worse efficacy with cenobamate depending on the other medications, meaning that it is not a particular combination that is responsible for the remarkable efficacy but cenobamate. Other studies have investigated the use of cenobamate in patients with more severe cases of epilepsy that have undergone surgery; the efficacy was again similar to what had been observed in other populations. A further subgroup analysis looked at the impact of cenobamate on dosing or continuation of other medications. This interview was recorded during an online conference call with The Video Journal of Neurology (VJNeurology).